Reuptake inhibitors are compounds that reduce the transporter-mediated return of released neurotransmitters from extracellular spaces into neurons or glial cells [1][2]. By slowing this clearance route, they can increase neurotransmitter availability near receptors and prolong extracellular signaling. Major targets include the serotonin, norepinephrine, and dopamine transporters, which use transmembrane ion gradients to drive neurotransmitter uptake. Individual inhibitors differ in their relative activity at these transporters, producing selective or combined inhibition profiles [1]. Structural studies show that several serotonin reuptake inhibitors occupy the central substrate-binding site and stabilize an outward-open transporter conformation, preventing normal serotonin binding and transport [3][4]. The broader category also includes inhibitors of non-monoamine transporters: glycine transporter 1 can be inhibited by compounds that stabilize an inward-open state [2]. Reuptake inhibition therefore describes interference with a transport process rather than a single binding geometry. Its immediate action is distinct from neurotransmitter synthesis inhibition, transmitter degradation blockade, or direct activation of a neurotransmitter receptor [1][2].